HRTX - Heron Therapeutics Inc Stock Price, Fair Value and News

$1.17-0.04 (-3.31%)

Delayed as of 03 Dec 2024, 11:53 am ET

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

HRTX Price Action

Last 7 days

6.1%

Last 30 days

-32.0%

Last 90 days

-30.1%

Trailing 12 Months

-8.3%

HRTX RSI Chart

HRTX Valuation

Market Cap

184.0M

Price/Earnings (Trailing)

-6.58

Price/Sales (Trailing)

1.34

EV/EBITDA

-53.3

Price/Free Cashflow

-19.63

HRTX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

HRTX Fundamentals

HRTX Revenue

Revenue (TTM)

137.7M

Rev. Growth (Yr)

4.38%

Rev. Growth (Qtr)

-8.92%

HRTX Earnings

Earnings (TTM)

-28.0M

Earnings Growth (Yr)

80.61%

Earnings Growth (Qtr)

47.5%

HRTX Profitability

EBT Margin

-8.30%

Return on Equity

69.91%

Return on Assets

-12.67%

Free Cashflow Yield

-5.09%

HRTX Investor Care

Shares Dilution (1Y)

1.35%

Diluted EPS (TTM)

-0.14

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	132.1M	136.4M	137.7M	0
2023	113.8M	118.0M	122.8M	127.0M
2022	89.8M	95.0M	98.3M	107.7M
2021	83.3M	83.0M	86.3M	86.3M
2020	139.8M	125.8M	103.1M	88.6M
2019	97.5M	116.9M	139.7M	146.0M
2018	38.7M	47.5M	58.7M	77.5M
2017	4.9M	13.4M	22.0M	30.8M
2016	0	0	0	1.5M
2011	1.5M	1.2M	825.0K	646.0K
2010	0	1.3M	1.3M	1.3M
2009	0	0	0	1.3M

Get all data in R, Python etc through our Historical Stock Data APIs

About Heron Therapeutics Inc

Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

CEO	Mr. Craig Alexander Collard
WEBSITE	herontx.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	203

Heron Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Heron Therapeutics Inc? What does HRTX stand for in stocks?

HRTX is the stock ticker symbol of Heron Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Heron Therapeutics Inc (HRTX)?

As of Mon Dec 02 2024, market cap of Heron Therapeutics Inc is 184.03 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of HRTX stock?

You can check HRTX's fair value in chart for subscribers.

Is Heron Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether HRTX is over valued or under valued. Whether Heron Therapeutics Inc is cheap or expensive depends on the assumptions which impact Heron Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for HRTX.

What is Heron Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Dec 02 2024, HRTX's PE ratio (Price to Earnings) is -6.58 and Price to Sales (PS) ratio is 1.34. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HRTX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Heron Therapeutics Inc's stock?

In the past 10 years, Heron Therapeutics Inc has provided -0.169 (multiply by 100 for percentage) rate of return.